Bruceine A Ameliorates Osteoporosis Through Suppression of RACK1 ‐Mediated Osteoclastogenesis
The FASEB Journal · 2025
DOI: 10.1096/fj.202502953r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Shenghui Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Hauptthemen laut MEDLINE: Receptors for Activated C Kinase, Osteoporosis, Osteoclasts, Osteogenesis. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Bejing Natural Science Foundation Joint Project, CAMS Innovation Fund for Medical Sciences (CIFMS), Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Bruceine A (BA) is a quassinoid compound derived from Brucea javanica with various pharmacological activities. Our previous work has revealed that BA exhibits anti‐inflammatory and glucose‐lowering effects in db/db mice, resulting in significant protection against diabetic kidney disease. However, considering the pivotal role of inflammatory signaling pathways during osteoclast differentiation, whether and how BA exerts protection against osteoporosis remains to be explored. In the present work, we have demonstrated that BA exhibits significant protective efficacy against bone loss in ovariectomized and diabetic mice, which mimic postmenopausal and diabetic osteoporosis, respectively. Moreover, BA is found to attenuate RANKL‐induced osteoclast differentiation and function in isolated bone marrow‐derived macrophages and the RAW264.7 cell line at non‐cytotoxic concentrations. Mechanistically, BA binds to RACK1 to disrupt the RACK1‐c‐SRC interaction, thereby suppressing the inflammatory signaling pathways involved in regulating osteoclastogenesis in a RACK1‐dependent manner. Altogether, our findings establish BA as a novel therapeutic agent for treating osteoporosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID-Profile: Shenghui Sun, Haozhe Zhang, Huiying Li, Hangjiang Ren, Jingyu Lin, Xiaoli Zhao, Zhen Wang
Förderung
- Bejing Natural Science Foundation Joint Project
- CAMS Innovation Fund for Medical Sciences (CIFMS)
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Sun, S., Zhang, H., Li, H., Ren, H., Lin, J., Zhao, X., & Wang, Z. (2025). Bruceine A Ameliorates Osteoporosis Through Suppression of RACK1 ‐Mediated Osteoclastogenesis. The FASEB Journal. https://doi.org/10.1096/fj.202502953r
Vancouver
Sun S, Zhang H, Li H, Ren H, Lin J, Zhao X, et al. Bruceine A Ameliorates Osteoporosis Through Suppression of RACK1 ‐Mediated Osteoclastogenesis. The FASEB Journal. 2025. doi:10.1096/fj.202502953r
BibTeX
@article{Sun2025,
author = {Sun, Shenghui and Zhang, Haozhe and Li, Huiying and Ren, Hangjiang and Lin, Jingyu and Zhao, Xiaoli and Wang, Zhen},
title = {Bruceine A Ameliorates Osteoporosis Through Suppression of RACK1 ‐Mediated Osteoclastogenesis},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202502953r}
}
EUVIMED